Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS

Abstract

ABSTRACT We identified two CRSwNP patients who had previously failed treatment with an anti‐IL‐4/IL‐13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti‐IL‐17 antibody (secukinumab). Anti‐IL‐17 antibody secukinumab was superior in reducing their NPS and SNOT‐22 values compared to dupilumab. IL‐17 could be a promising target for non‐type II and mixed endotype CRS treatment.

Keywords

• biological treatment
• biologics
• chronic rhinosinusitis with polyps
• CRSwNP
• dupilumab
• secukinumab